Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease

Journal of International Medical Research

Volumn 36, Issue 5, 2008, Pages 896-905

  Puri, Basant K ^a   Bydder, G M ^b   Manku, M S ^c   Clarke, A ^c   Waldman, A D ^a,d   Beckmann, C F ^e,f  

^a MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Amarin Neuroscience Limited   (United Kingdom)

^d CHARING CROSS HOSPITAL   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cerebral atrophy; Eicosapentaenoic acid; Huntington's disease

Indexed keywords

ICOSAPENTAENOIC ACID ETHYL ESTER; PLACEBO; DRUG DERIVATIVE; ETHYL EICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUNTINGTON CHOREA; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; THALAMUS POSTERIOR NUCLEUS; ANIMAL; ATROPHY; BRAIN CORTEX; DRUG EFFECT; HISTOLOGY; MIDDLE AGED; PATHOLOGY;

ANIMALS; ATROPHY; CEREBRAL CORTEX; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PLACEBOS;

EID: 54449085055     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600505     Document Type: Article

References (49)

1. Huntington's Disease Collaborative Research Group: A novel gene containing a trinudeotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
2. Kieburtz K, MacDonald M, Shih C, et al: Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet 1994; 31: 872-874.
3. Marder K, Zhao H, Myers RH, et al and the Huntington Study Group: Rate of functional decline in Huntington's disease. Neurology 2000; 54: 452-458.
4. Kirkwood SC, Su JL, Conneally PM, et al: Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol 2001; 58: 273-278.
5. Sawa A, Wiegand GW, Cooper J, et al: Increased apoptosis of Huntington's disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 1999; 5: 1194-1198.
6. Panov AV, Gutekunst CA, Leavitt BR, et al: Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002; 5: 731-736.
7. Liu YF: Expression of polyglutamine-expanded huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J Biol Chem 1998; 273: 28873-28877.
8. Yasuda S, Inoue K, Hirabayashi M, et al: Triggering of neuronal cell death by accumulation of activated SEK1 on nuclear polyglutamine aggregations in PML bodies. Genes Cells 1999; 4: 743-756.
9. Merienne K, Helmlinger D, Perkin GR, et al: Polyglutamine expansion induces a protein-damaging stress connecting heat shock protein 70 to the JNK pathway. J Biol Chem 2003; 278: 16957-16967.
10. Bae BI, Xu H, Igarashi S, et al: p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 2005; 47: 29-41.
11. Ryan AB, Zeitlin SO, Scrable H: Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis. Neurobiol Dis 2006; 24: 419-427.
12. Qin ZH, Wang Y, Chase TN: Stimulation of N-methyl-D-aspartate receptors induces apoptosis in rat brain. Barin Res 1996; 725: 166-177.
13. Qin ZH, Wang Y, Nakai M, et al: Transcription factor NF-κB contributes to excitotoxin-induced apotosis in rat striatum. Mol Pharmacol 1998; 53: 33-42.
14. Qin ZH, Chen RW, Wang Y, et a;: Nuclear factor κB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated aposptsis in rat striatum. J Neurosci 1999; 19: 4023-4033.
15. Serhan CN, Chiang N: Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol 2008; 153: S200-S215.
16. Ait-Said F, Elalamy I, Werts C, et al: Inhibition by eicosapentaenoic acid of IL-1β-induced PGHS-2 expression in human microvascular endothelial cells: involvement of lipoxygenase-derived metabolites and p38 MAPK pathway. Biochim Biophys Acta 2003; 1631: 77-94.
17. 2 induces caspase-dependent apoptosts in rat cortical cells. Neurosci Lett 2002; 317: 61-64.
18. 2 induced caspase-dependent apoptosis possibly through activation of EP2 receptors in cultured ippocampal neurons. Neurochem Int 2004; 45: 713-719.
19. Jump DB: The biochemistry of n-3 poly-unsaturated fatty acids. J Biol Chem 2002; 277: 8755-8758.
20. Murck H, Manku M: Ethyl-EPA in Huntington disease: potentially relevant mechanism of action. Brain Res Bull 2007; 72: 159-164.
21. Liu G, Bibus DM, Bode AM, et al: Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and cell transformation in JB6 cells. Proc Natl Acad Sci USA 2001; 98: 7510-7515.
22. Moon Y, Pestka JJ: Deoxynivalenol-induced mitogen-activated protein kinase phosphorylation and IL-6 expression In mice suppressed by fish oil. J Nutr Biochem 2003; 14: 717-726.
23. Lo CJ, Chiu KC, Fu M, et al: Fish oil modulates macrophage P44/P42 mitogen-activated protein kinase activity induced by lipopolysaccharide. J Parenter Enteral Nutr 2000; 24: 159-163.
24. Moon DO, Kim KC, Jin CY, et al: Inhibitory effects of eicosaperitaenoic acid on lipopolysaccharide-induced activation in BV2 microglia. Int Immunopharmacol 2007; 7: 222-229.
25. Minogue AM, Lynch AM, Loane DJ, et al: Modulation of amyloid-beta-induced and age-associated changes in rat hippocampus by eicosapentaenoic acid. J Neurochem 2007; 103: 914-926.
26. Lo CJ, Chiu KC, Fu M, et al: Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NFκB activity. J Surg Res 1999; 82: 216-221.
27. Zhao Y, Joshi-Barve S, Barve S, et al: Eicosapentaenoic acid prevents LPS-induced TNF-α expression by preventing NF-κB activation. J Am Coll Nutr 2004; 23: 71-78.
28. Frangou S, Lewis M,, Wollard J, et al: Preliminary in evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder. J Psychopharmacol 2007; 21: 435-439.
29. Vaddadi K: Dyskinesias and their treatment with essential fatty acids: a review. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 89-94.
30. Vaddadi KS, Soosai E, Chiu E, et al: A randomized, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport 2002; 13: 29-33.
31. Puri BK, Bydder GM, Counsell SJ, et al: MRI and neuropsychological improvement in Huntington disease following ethyl-EPA. Neuroreport 2002; 13: 123-126.
32. Puri BK, Leavitt BR, Hayden MR, et al: Ethyl-EPA in Huntington's disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005; 65: 286-292.
33. Puri BK: Monomodal rigid-body registration and applications to the investigation of the effects of eicosapentaenoic acid intervention in neuropsychiatric disorders. Prostaglandins Leukot Essent Fatty Acids 2004; 71: 177-179.
34. Koroshetz WJ: Huntington's disease. In: Office Practice of Neurology (Samuels MA, Feske S, eds). New York: Churchill Livingstone, 1996; pp: 654-661.
35. Huntington Study Group: Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11; 136-142.
36. Smith SM, De Stefano N, Jenkinson M, et al: Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001; 25: 466-475.
37. Smith SM, Zhang Y, Jenkinson M, et al: Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479-489.
38. Smith SM, Jenkinson M, Woolrich MW, et al: Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004; 23(suppl 1): S208-S219.
39. Smith SM: Fast robust automated brain extraction. Hum Brain Mapp 2002; 17: 143-155.
40. Jenkinson M, Smith SM: A global optimisation method for robust affine brain images. Med Image Anal 2001; 5: 143-156.
41. Jenkinson M, Bannister P, Brady M, et al: Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002; 17: 825-841.
42. Zhang Y, Brady M, Smith S: Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001; 20: 45-57.
43. Nicoll JAR: Neurodegenerative diseases, movement disorders and system degenerations. In: Adams & Graham's Introduction to Neuropathology, 3rd edn (Graham DI, Nicoll JAR, Bone I, eds). London: Hodder Arnold, 2006; pp 331-344.
44. Dom R, Malfroid M, Baro F: Neuropathology of Huntington's chorea. Studies of the ventrobasal complex of the thalamus. Neurology 1976; 26: 64-68.
45. Harper PS (ed): Huntington's Disease, 2nd edn. London: WB Saunders, 1996.
46. Aylward EH: Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res Bull 2007; 72: 152-158.
47. Jech R, Klempír J, Vymazal J, et al: Variation of selective gray and white matter atrophy in Huntington's disease. Mov Disord 2007; 22: 1783-1789.
48. Zimbelman JL, Paulsen JS, Mikos A, et al: fMRI detection of early neural dysfunction in preclinical Huntington's disease. J Int Neuropsychol Soc 2007; 13: 758-769.
49. Kavanagh T, Lonergan PE, Lynch MA: Eicosapentaenoic acid and gamma-linolenic acid increase hippocampal concentrations of IL-4 and IL-10 and abrogate lipopolysaccharide-induced inhibition of long-term potentiation. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 391-397.